前沿生物：2024年度业绩稳健增长，研发管线紧扣战略有序推进

Core Viewpoint - Frontier Biotech (688221) reported a strong performance in 2024 with total revenue of 129.47 million yuan, a 13.32% increase year-on-year, primarily driven by the growth of its innovative HIV drug, Aikening®, and diversified sales channels [1] Group 1: Financial Performance - The company significantly reduced its losses by 127.45 million yuan compared to the previous year, indicating robust development momentum [1] Group 2: Product Development and Market Strategy - Aikening® is the core product of Frontier Biotech, with comprehensive post-marketing research and academic promotion activities aimed at maximizing its clinical advantages and expanding its application range [1] - The company focuses on three key patient groups in outpatient settings: those with high viral loads, those not achieving antiviral treatment goals, and those with incomplete immune reconstitution, offering personalized treatment plans [1] - In inpatient settings, Aikening® has shown excellent treatment effects, leading to increased patient adherence and longer medication duration post-discharge [1] - The company is implementing a sales channel penetration strategy, enhancing accessibility of Aikening® in grassroots markets, with coverage in over 300 HIV treatment hospitals and 200 DTP pharmacies across 30 provinces and municipalities [1] Group 3: Research and Development - In 2024, the company invested 137 million yuan in post-marketing research for Aikening® and advancing pipeline products [2] - A first-in-class small nucleic acid drug candidate has entered the supportive research phase for new drug clinical trial applications, while a Phase II clinical trial for a new indication of Aikening® has been approved by the National Medical Products Administration [2] - The company’s FB4001 (teriparatide injection generic) is under review and is expected to be approved for commercialization in the U.S. by 2025 [2] - Academic research results for Aikening® have been published in international journals, demonstrating its effectiveness in specific patient populations and enhancing its influence in the academic community [2] Group 4: Future Outlook - The company is expected to continue its strong development trajectory in 2025, with increased R&D investment and market expansion efforts for Aikening® [3] - As R&D results materialize and market opportunities are explored, the company is poised for even more impressive performance in 2025 [3]